Published in final edited form as:

J Nutr Biochem. 2012 December ; 23(12): 1617–1626. doi:10.1016/j.jnutbio.2011.11.004.

Sulforaphane inhibits pancreatic cancer through disrupting Hsp90-p50^{Cdc37} complex and direct interactions with amino acids residues of Hsp90

Yanyan Li^{1,4,#}, G. Elif Karagöz^{2,#}, Young Ho Seo¹, Tao Zhang¹, Yiqun Jiang¹, Yanke Yu¹, Afonso M.S. Duarte², Steven J. Schwartz⁴, Rolf Boelens⁵, Kate Carroll³, Stefan G. D. Rüdiger², and Duxin Sun¹

¹Department of Pharmaceutical Sciences, University of Michigan, Michigan, USA ²Cellular Protein Chemistry, Bijvoet Center for Biomolecular Research, Utrecht University, Netherlands

³The Scripps Research Institute, Scripps Florida, USA ⁴Department of Food Science and Technology, Ohio State University, Ohio, USA ⁵Biomolecular NMR Spectroscopy, Bijvoet Center for Biomolecular Research, Utrecht University, Netherlands

Abstract

Sulforaphane [1-isothiocyanato-4-(methyl-sulfinyl) butane)], an isothiocyanate derived from cruciferous vegetables, has been shown to possess potent chemopreventive activity. We analyzed the effect of sulforaphane on the proliferation of pancreatic cancer cells. Sulforaphane inhibited pancreatic cancer cell growth *in vitro* with the IC₅₀'s around 10-15 μM and induced apoptosis. In pancreatic cancer xenograft mouse model, administration of sulforaphane showed remarkable inhibition of tumor growth without apparent toxicity noticed. We found that sulforaphane induced the degradation of heat shock protein 90 (Hsp90) client proteins and blocked the interaction of Hsp90 with its cochaperone p50^{Cdc37} in pancreatic cancer cells. Using Nuclear Magnetic Resonance Spectroscopy (NMR) with an isoleucine-specific labeling strategy, we overcame the protein size limit of conventional NMR and studied the interaction of sulforaphane with full-length Hsp90 dimer (170 kDa) in solution. NMR revealed multiple chemical shifts in sheet 2 and the adjacent loop in Hsp90 N-terminal domain after incubation of Hsp90 with sulforaphane. Liquid Chromatography coupled to Mass Spectrometry (LC-MS) further mapped a short peptide in this region that was tagged with sulforaphane. These data suggest a new mechanism of sulforaphane that disrupts protein-protein interaction in Hsp90 complex for its chemopreventive activity.

Keywords

sulforaphane; Hsp90; p50^{Cdc37}; NMR; pancreatic cancer

© 2011 Elsevier Inc. All rights reserved.

Address correspondence to: Duxin Sun, Ph.D., 428 Church Street, Rm 2020, Ann Arbor, MI 48109, USA. Phone: 1-734-615-8740; Fax: 1-734-615-6162; duxins@umich.edu. Stefan Rüdiger, Ph.D., Kruyt-Building, Padualaan 8, 3584 CH Utrecht, Netherlands. Phone: 31-30-253-3394; Fax: 31-30-254-0980; s.g.d.rudiger@uu.nl. Kate Carroll, Ph.D., 130 Scripps Way, Jupiter, FL 33458, USA. Phone: 1-561-228-2460; Fax: 1-561-228-2919; kcarroll@scripps.edu.

[#]These authors contribute equally to this paper.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1. Introduction

Numerous studies have shown the chemoprevention efficacy of high consumption of broccoli and broccoli sprouts against various cancers (1). Sulforaphane is a major compound from broccoli/broccoli sprouts to possess chemopreventive activity (2, 3). Previous studies suggest that sulforaphane modulates multiple targets (1, 4, 5), which regulates many cellular activities including oxidative stress, apoptosis induction, cell cycle arrest, angiogenesis and metastasis suppression, and detoxification of carcinogens (1, 6).

The regulation of multiple targets by sulforaphane may be through direct inhibition of each individual target, or through a common modulator that regulates multiple targets. Previous studies have shown that sulforaphane down-regulates a group of signaling proteins, such as Akt, cyclin-dependent kinase 4 (Cdk4), androgen receptor (AR), hypoxia-inducible factor-1 α (HIF-1 α), while these proteins are also client proteins of heat shock protein 90 (Hsp90). For instance, sulforaphane decreased Cdk4 protein level in ovarian cancer cells, leading to cell cycle arrest and apoptosis (7). Sulforaphane also down-regulated Akt, phosphorylated Akt, and phosphatidylinositol 3-kinase (PI3K) in ovarian cancer cells with a concomitant inhibition of Akt kinase activity (7). Sulforaphane reduced AR in prostate cancer cells (8, 9), and suppressed HIF-1 α in human tongue squamous cancer cells and prostate cancer cells (10). A recent study reported that sulforaphane enhanced acetylation of heat shock protein 90 (Hsp90) by inactivating histone deacetylase 6 (HDAC6) in prostate cancer cells, thereby inhibiting its association with AR, leading to destabilization of AR protein and disruption of AR signaling (8). Hsp90, an essential molecular chaperone, regulates the stability and maturation of a wide range of oncogenic client proteins (11, 12). Up to date, more than two hundred of Hsp90 client proteins have been identified, which includes mutated signaling proteins (Raf, p53), transmembrane tyrosine kinases (epidermal growth factor receptor 2 [HER-2], epidermal growth factor receptor [EGFR]), signaling proteins (Akt, HIF-1 α), and cell cycle regulators (Cdk4), hormone receptors (AR) (12, 13). It has become a promising target for cancer therapy.

In this study, we examined the anticancer effect of sulforaphane against pancreatic cancer cells and investigated the mechanism of Hsp90 modulation by sulforaphane. We did not observe hyperacetylation of Hsp90 in pancreatic cancer cells. We characterized the impact of sulforaphane on Hsp90-cochaperone interactions and ATP binding to Hsp90. Our data showed that sulforaphane inhibits Hsp90 through an ATP-binding independent manner. We revealed mechanistic insights in the regulation of Hsp90 by sulforaphane with Nuclear Magnetic Resonance Spectroscopy (NMR) technique and Liquid Chromatography coupled to Mass Spectrometry (LC-MS) peptide mapping.

2. Materials and Methods

2.1. Cell culture

Human pancreatic cancer cell lines Mia Paca-2, Panc-1, AsPc-1, and BxPc-3, were obtained from American Type Culture Collection. Authentication of these cell lines in their origin sources included morphology analysis, growth curve analysis, isoenzyme analysis, short tandem repeat analysis, and mycoplasma detection. Panc-1, AsPc-1, and BxPc-3 were maintained in RPMI1640 medium (Invitrogen) supplemented with 10% fetal bovine serum (Fisher Scientific) and 1% penicillin-streptomycin (Invitrogen). Mia Paca-2 was maintained in DMEM medium (Invitrogen) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin-glutamine.

2.2. Reagents

Sulforaphane was purchased from LKT Laboratories. The following antibodies were used for immunoblotting: Akt (Cell Signaling), p23^{Sba1} (Abcam), p53 mutant, Cdk4, p50^{Cdc37}, Hsp90, β -actin (Santa Cruz Biotechnology).

2.3. Western blotting analysis

After treatment, cells were harvested by washing twice with ice-cold PBS and lysed in RIPA lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 5 mM EDTA, 1 mM sodium orthovanadate, pH 7.5) supplemented with protease inhibitors (Pierce) on ice for 20 min. After centrifugation at 14,000 rpm for 15 min at 4 °C, the supernatant was recovered. Protein concentration was determined with BCA Protein Assay Reagents (Pierce). Equal amounts of protein were subject to SDS-PAGE, and transferred to PVDF membrane (BioRad). The membrane was then incubated with appropriate primary antibodies at 4 °C overnight, followed by 2 hr incubation with secondary antibodies at room temperature.

2.4. Triton-soluble and triton-insoluble protein fraction

Sulforaphane (15 μ M) was added after pre-incubation cells with 10 μ M MG132. After 24 hr treatment, cells were collected and lysed in a lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2 mM sodium orthovanadate, 5 mM sodium fluoride, 1 mM phenyl methyl sulfonyl fluoride and 5,000 U/ml aprotinin) on ice for 10 min. The samples were centrifuged at 16,000 g for 15 min at 4 °C, and the supernatant (triton-soluble fraction) was collected. The pellets (triton-insoluble fraction) were further lysed in 2% SDS in 50 mM Tris-HCl and boiled for 15 min.

2.5. MTS assay

Cells were seeded in 96-well microplates at a density of 3,000-5,000 cells per well. After 72 hr treatment with sulforaphane, cell viability was assessed by MTS assay (Promega) according to the manufacturer's instruction. The number of living cells is proportional to the absorbance at 490 nm.

2.6. Caspase-3 activity assay

Cells were treated with sulforaphane and collected after 24 hrs. Caspase-3 activity assay was based on the manufacturer's instruction of Caspase-3/CPP32 Fluorometric Assay Kit (Biovision Research Products). The cleavage of a caspase-3 substrate was quantified by using a fluorescence microtiter plate reader with a 400 nm excitation filter and a 505 nm emission filter.

2.7. Pancreatic cancer xenograft

The animal study protocol was approved by the University Committee on Use and Care of Animals (UCUCA) at University of Michigan. Four- to six-week-old athymic (nu/nu) female mice were obtained from NCI. Mia Paca-2 cells (5×10^6 - 10×10^6) mixed with Matrigel were subcutaneously implanted into the right and left flanks of the mice. Tumor volume was calculated with $V = 1/2 (\text{width}^2 \times \text{length})$. After tumor volume reached 100-150 mm³, mice were randomized into three groups for treatment. The mice were i.p. injected with vehicle (saline), 25 mg/kg or 50 mg/kg sulforaphane (five times per week) for four weeks. Tumor size was monitored twice a week and normalized to the initial volumes.

2.8. Protein cloning, expression, and purification

The plasmid pET28a(+)-hHsp90 β (529-723) for expression of human Hsp90 β C (Hsp90 β -G529-D723) was kindly provided by Dr. Thomas Ratajczak (University of Western

Australia). The purified Hsp90 β N protein (Hsp90 β -P1-E245) was kindly provided by Dr. Dan Bolon (University of Massachusetts Medical School). The plasmid was transformed into *Escherichia coli* strain Rosetta 2(DE3) (EMD Biosciences Inc.) according to the protocol provided by manufacturer. Protein expression was induced by 0.2 mM IPTG. His-tagged protein was purified by affinity chromatography through mixing with HisPurTM Cobalt Resin (Pierce). Purified protein was dialyzed against PBS, and the purity was assessed by SDS-PAGE. Protein was stored at -70 °C after adding glycerol to 10%.

2.9. ATP-sepharose binding assay

Cells were treated with sulforaphane for 24 hrs, and then lysed in TNESV buffer (50 mM Tris, 2 mM EDTA, 100 mM NaCl, 1 mM Na₃VO₄, 25 mM NaF, 1% Triton X-100, pH 7.5) supplemented with protease inhibitors at 4 °C for 30 min. Protein (200 μ g) was incubated with 25 μ l pre-equilibrated γ -phosphate-linked ATP-sepharose (Jena Bioscience GmbH) in 200 μ l incubation buffer (10 mM Tris-HCl, 50 mM KCl, 5 mM MgCl₂, 20 mM Na₂MoO₄, 0.01% NP-40, pH 7.5) overnight at 4 °C. The protein bound to sepharose beads were analyzed by Western blotting.

2.10. Hsp90 co-immunoprecipitation

Cells were treated with sulforaphane for 24 hrs, and lysed in 20 mM Tris-HCl (pH 7.4), 25 mM NaCl, 2 mM DTT, 20 mM Na₂MoO₄, 0.1% NP-40, and protease inhibitors. Protein (500 μ g) was incubated with H9010 antibody (Axxora) for 1 hr at 4 °C, followed by overnight incubation with protein A/G agarose at 4 °C. The bound proteins were analyzed by Western blotting.

2.11. Proteolytic fingerprinting assay

Purified protein (0.5 μ g) was pre-incubated with DMSO or sulforaphane in assay buffer (10 mM Tris-HCl, 50 mM KCl, 5 mM MgCl₂, 0.1 mM EDTA, pH 7.4) on ice for 1 hr, and was digested with trypsin for 6 min. The reaction was terminated by adding SDS buffer and boiling for 3-5 min. The digested products from Hsp90 β N (Hsp90 β -P1-E245) and Hsp90 β C (Hsp90 β -G529-D723) were analyzed by Western blotting with Hsp90 antibody (N-17, Santa Cruz Biotechnology) and Hsp90 (AC88) antibody (Assay Designs, Inc., Ann Arbor, MI), respectively.

2.12. LC-MS

Hsp90 β N (Hsp90 β -P1-E245, 80 μ M) was incubated with DMSO or sulforaphane in PBS at 37 °C for 30 min. Small molecules were removed by gel filtration using P-30 micro Bio-Spin columns. Samples were analyzed on Shimadzu LCMS-2010EV after separation on a PLRP-S polymeric RP-HPLC column (50 $\times$ 2.1 mm, 1000 $\text{\AA}$, 5 μ m) with a gradient of 5% to 35% B in 30 min (A: 0.1% formic acid in H₂O; B: 0.1% formic acid in CH₃CN) at a flow rate of 0.2 ml/min. For peptide mapping, Hsp90 β N (80 μ M) was incubated with DMSO or sulforaphane (2 mM) for 30 min, and was then treated with DTT (10 mM) for 1 hr, followed by Sequencing Grade Modified Trypsin (Promega) for 24 hrs at 37 °C. Samples were analyzed on a Vydac Everest reverse-phase C18 monomeric column (250 $\times$ 2.1 mm, 300 $\text{\AA}$, 5 μ m) with a gradient of 5% to 65% B in 60 min at a flow rate of 0.2 ml/min.

2.13. NMR spectroscopy

Hsp90 was recombinantly produced with N-terminal hexa-histidine tag and specifically methyl labeled at Ile side chains as described (14). The NMR experiments were performed with 150 μ M of Hsp90 in 100% D₂O, 25 mM sodium phosphate, pH 7.2, 300 mM NaCl, 1 mM TCEP, and sulforaphane concentration was varied (dissolved in deuterated DMSO, final concentration 1% at 1.5 mM sulforaphane) for NMR measurements. ¹³C-¹H-methyl

TROSY spectra (15) were recorded at 25°C on a Bruker AvanceII 900 MHz spectrometer equipped with a TCI cryoprobe. Reported chemical shifts are referenced against DSS, and processing and peak position plots were done as described (14). The cross peaks of the methyl-TROSY spectra were 2D-line shape fitted using mixed Lorentzian/Gaussian deconvolution parameters (TopSpin). The rainbow spectra indicate increasing intensity from blue to red over 14 contour levels. All contours above the intensity of the cross peak at 0.72 ppm (^1H) and 10.8 ppm (^{13}C) are red. Comparisons with Hsp90 in the absence of sulforaphane were corrected for DMSO effects.

2.14. Statistical analysis

Statistical analysis was performed using student t-test. Data are presented as mean $\pm$ SD (n 3, $P < 0.01$ or < 0.05).

3. Results

3.1. Sulforaphane induces proteasomal degradation of Hsp90 client proteins in pancreatic cancer cells

We first examined whether sulforaphane could reduce the levels of Hsp90 client proteins, Akt, Cdk4, and p53 mutant, in Mia Paca-2 and Panc-1. Both cell lines contain p53 mutant and activated Ras (16-18). As shown in Fig. 1a and 1b, the levels of these proteins declined in a time- and concentration-dependent manner in response to sulforaphane treatment. Sulforaphane (15 μM) down-regulated Akt, Cdk4, and p53 mutant by 70-95% after 48 hrs, and 25 μM of sulforaphane decreased these client proteins by 80-95% after 24 hrs (Fig. 1a & 1b).

We further investigated whether sulforaphane-induced Hsp90 client protein down-regulation was through proteasomal degradation. MG132, a well-known proteasome inhibitor, was pre-incubated with pancreatic cancer cells to block proteasome function. Inhibition of proteasome leads to accumulation of unfolded proteins, which form insoluble “aggresomes” in the triton-insoluble fraction of cell lysates. As shown in Fig. 1c, Akt and Cdk4 were found to accumulate in the triton-insoluble fraction after sulforaphane treatment in the presence of MG132, while they were undetectable in triton-insoluble fraction after sulforaphane treatment alone. These data indicate that sulforaphane induced proteasomal degradation of Hsp90 client proteins in pancreatic cancer cells.

3.2. Sulforaphane inhibits pancreatic cancer cells in vitro and exhibits anticancer activity in pancreatic cancer xenograft

We evaluated the anti-proliferative activity of sulforaphane in human pancreatic cancer cell lines, Mia Paca-2, Panc-1, AsPc-1, and BxPc-3, by MTS cell proliferation assay. After treatment with increasing concentrations of sulforaphane for 72 hrs, the percentage of viable cells relative to untreated cells is plotted in Fig. 2a. Cell viability decreased as the concentration of sulforaphane increased in a similar pattern among all the four cell lines, with the IC_{50} 's around 10-15 μM . Then we used Mia Paca-2 to illustrate the effect of sulforaphane on caspase-3 activation. The results of caspase-3 assay showed that sulforaphane induced activation of caspase-3 in a concentration-dependent manner (Fig. 2b). In comparison with control cells, 10 μM sulforaphane was able to enhance the caspase-3 activity to more than 3-fold ($P = 0.003$), and more than a 4-fold increase was observed when cells were exposed to 15 μM sulforaphane ($P = 0.001$). These data suggest that sulforaphane inhibits pancreatic cancer cell growth and induces apoptosis *in vitro*.

We next evaluated the efficacy of sulforaphane in Mia Paca-2 xenograft model. Two weeks after cancer cell implantation, the mice were injected (i.p.) with either vehicle or

sulforaphane at 25 mg/kg or 50 mg/kg for 1 month. At the end of treatment, control tumors reached an average size of $715 \pm 66 \text{ mm}^3$, while 25 mg/kg and 50 mg/kg sulforaphane treatment limited the tumor volumes to $538 \pm 88 \text{ mm}^3$ and $354 \pm 52 \text{ mm}^3$, respectively (Fig. 2c). These correspond to 25% ($P = 0.002$) and 50% ($P = 0.0001$) inhibition of tumor growth. Meanwhile, sulforaphane showed no apparent toxicity as determined by body weight measurement (Fig. 2d).

3.3. Sulforaphane inhibits Hsp90 by blocking Hsp90-p50^{Cdc37} complex in pancreatic cancer cells

Most Hsp90 inhibitors, e.g., 17-AAG, bind to Hsp90 N-terminal ATP pocket, preventing the maturation of Hsp90 client proteins (19). However, sulforaphane (5–30 μM) was unable to decrease the amount of ATP-bound Hsp90 (Fig. 3a), which suggests that sulforaphane did not affect the ATP-binding capacity of Hsp90. As positive control, 17-AAG (5 μM) blocked the ATP binding to Hsp90 and decreased the amount of ATP-bound Hsp90 in the ATP-sepharose binding assay. Since Hsp90 chaperone function depends on multiple cochaperones to form the complexes, we investigated the effect of sulforaphane on Hsp90-cochaperone interaction using co-immunoprecipitation assay. We found that sulforaphane inhibited Hsp90 and p50^{Cdc37} interaction. Sulforaphane (15–30 μM) treatment for 24 hrs in Mia Paca-2 cells reduced the amount of p50^{Cdc37} co-precipitated with Hsp90 by approximately 3- to 5-fold (Fig. 3b). However, sulforaphane (15–30 μM) did not change the amount of p23^{Sba1} in precipitated Hsp90 complex. The total protein levels of Hsp90, p50^{Cdc37}, and p23^{Sba1} were unchanged after sulforaphane treatment (Fig. 3b). These data suggest that sulforaphane blocked Hsp90-p50^{Cdc37} interaction, but not Hsp90-p23^{Sba1} interaction.

3.4. NMR reveals the sulforaphane binding sites on Hsp90

To investigate whether sulforaphane directly modulates Hsp90, we employed the NMR spectroscopy for full-length Hsp90. (14, 15, 20, 21). Conventional NMR methods are restricted to proteins up to 50 kDa, however, complexes of full-length Hsp90 dimer with cofactors are around 200 kDa, which poses challenges for this study. Recently, the Kay laboratory performed pioneering NMR spectroscopy for large proteins by specific labeling of methyl groups of aliphatic amino acids, including isoleucine (Ile), to overcome the limitations (23, 24). Here we applied the similar strategy.

When comparing the NMR spectra of Hsp90 in the absence and presence of sulforaphane, a subset of peaks shifts (Fig. 4a and 4b). We assigned the N-terminal and middle domains of Hsp90 (14), which allowed us to map the chemical shifts within those domains (Fig. 4c). Two binding clusters were particularly intriguing. We found chemical shifts in sheet 2 for Ile 74 and Ile 75 in the N-terminal domain (Fig. 4d). The signals of Ile 43 and Ile 125 are also shifting (Fig. 4e). Ile 43 is found in α -helix in the neighborhood of Ile 74 and the change of environment of this residue might have affected Ile 43 indirectly. Ile 125, which belongs to the p50^{Cdc37} interaction interface (Fig. 4e), shifts upon sulforaphane interaction, but the nearby Ile 122 is not affected. This indicates that Ile 125 shifting is likely caused by an allosteric effect, which may disturb the interaction between p50^{Cdc37} and Hsp90.

In the middle domain, we also identified chemical shifts in four isoleucines (Fig. 4c). Three of those (Ile 369, Ile 440 and Ile 482) are sufficiently close to Cys side chains, which in other proteins are known to undergo reaction with sulforaphane. Cys 365 is 6.3 Å away from Ile 369 and Cys 520 is 5.3 Å and 13.6 Å away from Ile 440 and Ile 482 respectively. Ile 287 is found in the loop in the interface of the N-terminal and middle domain of Hsp90 and this could be shifting due to change in the domain orientation.

At present, no assignment of the C-terminal domain is available. For the three residues we identified in the C-terminal domain, we did not observe sulforaphane-dependent shifts. This indicates that sulforaphane did not have effects on Hsp90 C-terminal domain, despite harboring four out of six cysteines.

Comparing to the spectra of sulforaphane-free Hsp90, we noted line broadening for a subset of signals. Those signals reside in the region of unstructured and dynamic segments which indicated an effect of sulforaphane on Hsp90 dynamics. As controls, we also compared the sulforaphane-dependent shifts with those of nucleotides and the ATP binding inhibitor geldanamycin (14). While all of those ligands show a coherent pattern clustering around the nucleotide binding pocket, sulforaphane binds in a different mode. The NMR data further confirms that sulforaphane does not block the nucleotide binding of Hsp90, in agreement with the results of ATP-sepharose binding assay (Fig. 3a). In addition, we also analyzed whether sulforaphane binding could have any effect on binding of co-chaperones p23^{Sba1} (Fig. 4c). The p23^{Sba1} binding site in Hsp90 is not affected by sulforaphane, so direct obstruction of the binding interface for them is unlikely.

3.5. Proteolytic fingerprinting and LC-MS detect sulforaphane binding with Hsp90

We next examined the interaction of Hsp90 with sulforaphane using isolated protein domains. We first performed proteolytic fingerprinting assay to test if sulforaphane can bind to Hsp90 N-terminus. In the absence of sulforaphane, the N-terminal domain of Hsp90 (Hsp90N, Hsp90-P1-E245) was highly sensitive to trypsin digestion. Pre-incubation of sulforaphane with Hsp90N prevented it from trypsin hydrolysis, with a strong band representing intact Hsp90N even at a high concentration of trypsin (Fig. 5a). However, very slight difference was observed between control and treatment upon trypsin digestion when sulforaphane was incubated with Hsp90 C-terminus (Hsp90βC, Hsp90β-G529-D723) (Fig. 5b).

We next conducted LC-MS analysis of Hsp90N domain to characterize the interaction with sulforaphane. After incubation with 2 mM sulforaphane, the mass spectrum of Hsp90N exhibited a mass increase which corresponded to the molecular weight of one sulforaphane molecule (Fig. 5c). Further peptide mapping study indicated that a short peptide Ile 72-Arg 81 (IDIIPNPQER) was tagged with sulforaphane (Fig. 5d). The LC-MS data are in agreement with the NMR findings because chemical shift changes (Ile 74 and Ile 75) identified was located in this peptide. These results suggest that sulforaphane covalently interacts with Hsp90N.

4. Discussion

Pancreatic cancer is one of the leading causes of cancer death in the United States (22). The currently available therapeutics (such as gemcitabine) have shown very limited success on treatment of this aggressive disease (23). Given that pancreatic carcinogenesis is characterized by complex molecular basis that are involved many oncogenic proteins, Hsp90, an essential molecular chaperone that regulates the stability and maturation of a wide range of oncogenic proteins, may provide advantages as a promising target for pancreatic cancer therapeutics (11, 12). Inhibition of Hsp90 may result in simultaneous degradation of multiple client proteins, such as kinases, hormone receptors, and transcription factors in cancers (12, 13). Among these proteins phosphoinositide 3-OH kinase (PI3K)/Akt pathway and p53 mutant are important molecular targets in pancreatic cancer (24, 25). K-Ras mutation is known to occur in approximately 90% of human pancreatic ductal adenocarcinomas (22, 26); and PI3K/Akt is a critical effector pathway of activated K-Ras (22, 27). Moreover, PI3K/Akt pathway is constitutively active in the majority of pancreatic cancer (22, 28); and amplification or activation of Akt2 is encountered in up to 60% of

pancreatic cancer (22, 25, 29). Over-expression or activation of p53 mutant is a critical event in human pancreatic carcinogenesis as well (24). Thus, interference with Hsp90 function and subsequent down-regulation of these client proteins provides a rational strategy to abrogate signaling against pancreatic cancer.

In the current study, we show that sulforaphane, a dietary component from broccoli/broccoli sprouts, inhibits Hsp90 chaperone function and promotes proteasomal degradation of Hsp90 client proteins (Fig. 1), resulting in pancreatic cancer cell death (Fig. 2). Sulforaphane has been reported as a potent chemoprevention agent, which provides many advantages over traditional Hsp90 inhibitors, including high bioavailability and low toxicity (6). Sulforaphane from broccoli extracts is efficiently and rapidly absorbed in human small intestine, and quickly distributed throughout the body (1, 30). Although the accumulation of sulforaphane in human pancreas tissue is not clear yet, plasma concentrations of sulforaphane equivalents reached as micromolar concentrations in the blood after administration of a single dose of 200 μ mol broccoli sprout isothiocyanates (mainly sulforaphane) (31). Clinical trials have shown that oral administration of 25 μ mol isothiocyanates (primarily sulforaphane) at 8-hr intervals for 7 days or consumption of broccoli sprout solution containing 400 μ mol glucoraphanin (precursor of sulforaphane) daily for 2 weeks is well tolerated with no significant toxicity in human subjects (32, 33).

Hsp90 consists of an N-terminal ATP-binding domain (Hsp90-P1-E245), a middle domain (Hsp90-K246-D528) and a C-terminal dimerization domain (Hsp90-G529-D723) (34, 35). Since Hsp90 chaperone function depends on the conformational changes driven by its ATPase activity (19), numerous Hsp90 inhibitors, represented by geldanamycin and 17-AAG, have been developed to inhibit its chaperone function by interfering with ATP binding (36). These small molecules competitively bind to the deep ATP pocket of Hsp90, thereby blocking the ATPase cycle and result in proteasomal degradation of its client proteins (37, 38). Although 17-AAG has entered clinical trials, its hepatotoxicity, low water solubility, low oral bioavailability, may limit its application (39). Recently, our group has demonstrated that disruption of Hsp90-p50^{Cdc37} complex inhibits Hsp90 chaperone function and induces degradation of Hsp90 client proteins, leading to anticancer activity (40-42).

In contrast to the classical Hsp90 inhibitors, sulforaphane impaired Hsp90 chaperone function by blocking formation of the Hsp90-p50^{Cdc37} complex (Fig. 1 & 3), and it did not enter the ATP binding pocket (Fig. 3a), therefore, the mechanism of action is clearly different from other drugs such as geldanamycin, 17-AAG or radicicol. Incubation of sulforaphane with full-length Hsp90 dimer induced multiple chemical shifts (Fig. 4). Higher concentration of sulforaphane was used to incubate with Hsp90, because previous studies have indicated that sulforaphane accumulated in cells when added to culture medium and resulted in millimolar concentrations in cellular lysates (43) [moved from section 3.3]. The shift of Ile 125, which belongs to the Hsp90-p50^{Cdc37} interface, may affect the interaction (Fig. 4e). Most of the other Ile shifts caused by sulforaphane do not belong to the interface of Hsp90-p50^{Cdc37} (Fig. 4). For example, sulforaphane interacts with the sheet 2 of Hsp90 N-terminal domain and its adjacent loop and covalently modifies the short peptide IDIIPNPQER covering that region (Fig. 4 & 5). This kind of interaction may induce dramatic allosterical effect. Using the isolated N-terminal domain of Hsp90, sulforaphane can protect the entire domain from trypsin digestion (Fig. 5a). Other mechanisms may be involved as well. Literatures reported that sulforaphane can mediate chemopreventive effects through its ability to react with thiol groups of cysteine in target proteins (44), such as Keap1 (45) and cFos (44). We mapped the six cysteine residues on Hsp90 and noted that only Cys 365 is to a minor extent solvent accessible, all others are entirely buried. The Cys 365 is close to the shifted isoleucine 369 in the middle domain identified by NMR (Fig. 4c). Two other shifted isoleucine 440 and 482 are close to Cys 520 (Fig. 4c). At present, no

NMR assignment of the C-terminal domain is available, but we could identify three residues that could be allocated to the C-terminal domain. For those three residues we did not observe sulforaphane-dependent shifts (Figs. 4ab). The NMR data cannot fully exclude, though, that sulforaphane might interact with flexible areas in the C-terminus. The dynamic segments of Hsp90 correspond to the large area around the cross peak at 0.85 (^1H) and 12.5 (^{13}C), which shows line broadening upon sulforaphane binding. This may indicate an effect of sulforaphane on the dynamics in Hsp90.

In comparison, our data suggest that sulforaphane did not affect Hsp90-p23^{Sba1} interaction (Fig. 3b & 4c), although p23^{Sba1} binds to a similar region of Hsp90 as p50^{Cdc37} does. The crystal structures of Hsp90-p50^{Cdc37} and Hsp90-p23^{Sba1} complex may provide some clues for the specificity. The p50^{Cdc37} binding Hsp90 is in an open confirmation with small conformational changes compared with nucleotide-free structure (46). The majority of the interaction involves Met 164, Leu 165, Ala 204, and Leu 205 of p50^{Cdc37}, and Ala 103, Ala 107, Ala 110, Gly 111, Ala 112, Met 116 and Phe 120 of Hsp90 (46). Results of our recent split Renilla luciferase protein fragment-assisted complementation (SRL-PFAC) bioluminescence assay have shown that mutation of a single amino acid can reduce the Hsp90-p50^{Cdc37} interaction by 70-95% (47). Thus, it is not surprising that binding of sulforaphane to Hsp90 and p50^{Cdc37} resulted in disruption of the complex. By contrast, extensive interaction interface is involved in Hsp90-p23^{Sba1} complex when p23^{Sba1} binds to the ATP-bound, closed confirmation of Hsp90, which may make this interface less sensitive to sulforaphane.

A very recent study found that sulforaphane regulated Hsp90 function by changing its acetylation status. Sulforaphane was shown to inhibit HDAC6 enzyme activity to induce hyperacetylation of Hsp90 in prostate cancer cells, thereby leading to destabilization of androgen receptor (AR), a client protein of Hsp90 (8). The data showed an increased amount of Hsp90 immunoprecipitated with acetyl-lysine. However, we did not observe Hsp90 hyperacetylation with immunoprecipitation of either acetyl-lysine (followed by immunoblotting of Hsp90) or Hsp90 (followed by immunoblotting of acetyl-lysine) in pancreatic cancer cells. This discrepancy could come from different cancer cells or different experimental settings. In addition, previous studies showed that HDAC6 inhibition by HDAC6 knockdown and LBH589 decreased ATP binding to Hsp90 and Hsp90- p23^{Sba1} complex, but not Hsp90- p50^{Cdc37} interaction (48). Our data suggest that sulforaphane inhibits Hsp90 and disrupts Hsp90- p50^{Cdc37} complex through a different mechanism than HDAC inhibition, in which the direct modifications of specific amino acid residues of Hsp90 is one of plausible mechanisms to block the Hsp90- p50^{Cdc37} interaction.

It is worth noting that sulforaphane may modify other proteins in the Hsp90 complex. For instance, a very recent proteomics study has shown heat shock protein 70 (Hsp70) as a potential protein target for sulforaphane modification (49). These new findings warrant further investigation for the new molecular targets of sulforaphane.

In summary, our study has shown that sulforaphane inhibits pancreatic cancer cell growth *in vitro* and suppresses tumor growth *in vivo* in xenograft mouse models. We revealed a mechanism indicating that sulforaphane directly interacts with specific amino acid residues of Hsp90, disrupts Hsp90-p50^{Cdc37} complex, inhibits Hsp90 chaperone function, and induces degradation of Hsp90 client proteins.

Acknowledgments

We thank Dr. Dan Bolon (University of Massachusetts Medical School) for the generous gifts of the purified Hsp90 β N protein. We also thank Dr. Thomas Ratajczak (University of Western Australia) for kindly providing us with the expression plasmid pET28a(+)-hHsp90 β (529-723).

Grant support: This work was supported by NIH (RO1 CA120023, RO1 CA122906-01A1, and R21 CA143474); University of Michigan Cancer Center Research Grant; University of Michigan Cancer Center Core Grant to D. S.; Marie-Curie Excellence Grant of the EU; VIDI career development grant by the Netherlands Organization for Scientific Research NOW; and a High Potential Grant of Utrecht University; NWO-CW for the 900 MHz NMR and the TCI cryoprobe.

References

- Clarke JD, Dashwood RH, Ho E. Multi-targeted prevention of cancer by sulforaphane. *Cancer Lett.* 2008; 269:291–304. [PubMed: 18504070]
- Conaway CC, Wang CX, Pittman B, et al. Phenethyl isothiocyanate and sulforaphane and their N-acetylcysteine conjugates inhibit malignant progression of lung adenomas induced by tobacco carcinogens in A/J mice. *Cancer Res.* 2005; 65:8548–57. [PubMed: 16166336]
- Fahey JW, Zhang Y, Talalay P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. *Proc Natl Acad Sci U S A.* 1997; 94:10367–72. [PubMed: 9294217]
- Li Y, Zhang T, Korkaya H, et al. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. *Clin Cancer Res.* 16:2580–90. [PubMed: 20388854]
- Juge N, Mithen RF, Traka M. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. *Cell Mol Life Sci.* 2007; 64:1105–27. [PubMed: 17396224]
- Zhang Y, Tang L. Discovery and development of sulforaphane as a cancer chemopreventive phytochemical. *Acta Pharmacol Sin.* 2007; 28:1343–54. [PubMed: 17723168]
- Chaudhuri D, Orsulic S, Ashok BT. Antiproliferative activity of sulforaphane in Akt-overexpressing ovarian cancer cells. *Mol Cancer Ther.* 2007; 6:334–45. [PubMed: 17237292]
- Gibbs A, Schwartzman J, Deng V, Alumkal J. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. *Proc Natl Acad Sci U S A.* 2009; 106:16663–8. [PubMed: 19805354]
- Kim SH, Singh SV. D,L-Sulforaphane causes transcriptional repression of androgen receptor in human prostate cancer cells. *Mol Cancer Ther.* 2009; 8:1946–54. [PubMed: 19584240]
- Yao H, Wang H, Zhang Z, Jiang BH, Luo J, Shi X. Sulforaphane inhibited expression of hypoxia-inducible factor-1alpha in human tongue squamous cancer cells and prostate cancer cells. *Int J Cancer.* 2008; 123:1255–61. [PubMed: 18561315]
- Smith JR, Workman P. Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning. *Cell Cycle.* 2009; 8:362–72. [PubMed: 19177013]
- Kamal A, Boehm MF, Burrows FJ. Therapeutic and diagnostic implications of Hsp90 activation. *Trends Mol Med.* 2004; 10:283–90. [PubMed: 15177193]
- Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. *Nat Rev Cancer.* 2005; 5:761–72. [PubMed: 16175177]
- Karagoz GE, Duarte AM, Ippel H, et al. N-terminal domain of human Hsp90 triggers binding to the cochaperone p23. *Proc Natl Acad Sci U S A.* 2011; 108:580–5. [PubMed: 21183720]
- Tugarinov V, Hwang PM, Kay LE. Nuclear magnetic resonance spectroscopy of high-molecular-weight proteins. *Annu Rev Biochem.* 2004; 73:107–46. [PubMed: 15189138]
- Butz J, Wickstrom E, Edwards J. Characterization of mutations and loss of heterozygosity of p53 and K-ras2 in pancreatic cancer cell lines by immobilized polymerase chain reaction. *BMC Biotechnol.* 2003; 3:11. [PubMed: 12877750]
- Mohiuddin M, Chendil D, Dey S, Alcock RA, Regine W, Ahmed MM. Influence of p53 status on radiation and 5-fluorouracil synergy in pancreatic cancer cells. *Anticancer Res.* 2002; 22:825–30. [PubMed: 12014658]
- Alcock RA, Dey S, Chendil D, et al. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2. *Oncogene.* 2002; 21:7883–90. [PubMed: 12420225]
- Neckers L. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification. *Curr Med Chem.* 2003; 10:733–9. [PubMed: 12678776]

20. Bertelsen EB, Chang L, Gestwicki JE, Zuiderweg ER. Solution conformation of wild-type E. coli Hsp70 (DnaK) chaperone complexed with ADP and substrate. *Proc Natl Acad Sci U S A*. 2009; 106:8471–6. [PubMed: 19439666]
21. Sprangers R, Kay LE. Quantitative dynamics and binding studies of the 20S proteasome by NMR. *Nature*. 2007; 445:618–22. [PubMed: 17237764]
22. Koorstra JB, Hustinx SR, Offerhaus GJ, Maitra A. Pancreatic carcinogenesis. *Pancreatol*. 2008; 8:110–25. [PubMed: 18382097]
23. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. *Lancet*. 2004; 363:1049–57. [PubMed: 15051286]
24. Barton CM, Staddon SL, Hughes CM, et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. *Br J Cancer*. 1991; 64:1076–82. [PubMed: 1764370]
25. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. *Br J Cancer*. 2003; 89:2110–5. [PubMed: 14647146]
26. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. *Cell*. 1988; 53:549–54. [PubMed: 2453289]
27. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. *Nat Rev Cancer*. 2002; 2:489–501. [PubMed: 12094235]
28. Reichert M, Saur D, Hamacher R, Schmid RM, Schneider G. Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. *Cancer Res*. 2007; 67:4149–56. [PubMed: 17483325]
29. Altomare DA, Tanno S, De Rienzo A, et al. Frequent activation of AKT2 kinase in human pancreatic carcinomas. *J Cell Biochem*. 2002; 87:470–6. [PubMed: 14735903]
30. Petri N, Tannergren C, Holst B, et al. Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. *Drug Metab Dispos*. 2003; 31:805–13. [PubMed: 12756216]
31. Ye L, Dinkova-Kostova AT, Wade KL, Zhang Y, Shapiro TA, Talalay P. Quantitative determination of dithiocarbamates in human plasma, serum, erythrocytes and urine: pharmacokinetics of broccoli sprout isothiocyanates in humans. *Clin Chim Acta*. 2002; 316:43–53. [PubMed: 11750273]
32. Shapiro TA, Fahey JW, Dinkova-Kostova AT, et al. Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. *Nutr Cancer*. 2006; 55:53–62. [PubMed: 16965241]
33. Kensler TW, Chen JG, Egner PA, et al. Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. *Cancer Epidemiol Biomarkers Prev*. 2005; 14:2605–13. [PubMed: 16284385]
34. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. *Cell*. 1997; 90:65–75. [PubMed: 9230303]
35. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. *Cell*. 1997; 89:239–50. [PubMed: 9108479]
36. Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. *Ann N Y Acad Sci*. 2007; 1113:202–16. [PubMed: 17513464]
37. Neckers L. Chaperoning oncogenes: Hsp90 as a target of geldanamycin. *Handb Exp Pharmacol*. 2006:259–77. [PubMed: 16610363]
38. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. *Proc Natl Acad Sci U S A*. 1994; 91:8324–8. [PubMed: 8078881]

39. Usmani SZ, Bona R, Li Z. 17 AAG for HSP90 inhibition in cancer--from bench to bedside. *Curr Mol Med*. 2009; 9:654–64. [PubMed: 19601813]
40. Zhang T, Hamza A, Cao X, et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. *Mol Cancer Ther*. 2008; 7:162–70. [PubMed: 18202019]
41. Yu Y, Hamza A, Zhang T, et al. Withaferin A targets heat shock protein 90 in pancreatic cancer cells. *Biochem Pharmacol*. 2009
42. Zhang T, Li Y, Yu Y, Zou P, Jiang Y, Sun D. Characterization of celastrol to inhibit HSP90 and CDC37 interaction. *J Biol Chem*. 2009
43. Zhang Y. Role of glutathione in the accumulation of anticarcinogenic isothiocyanates and their glutathione conjugates by murine hepatoma cells. *Carcinogenesis*. 2000; 21:1175–82. [PubMed: 10837007]
44. Dickinson SE, Melton TF, Olson ER, Zhang J, Saboda K, Bowden GT. Inhibition of activator protein-1 by sulforaphane involves interaction with cysteine in the cFos DNA-binding domain: implications for chemoprevention of UVB-induced skin cancer. *Cancer Res*. 2009; 69:7103–10. [PubMed: 19671797]
45. Hong F, Freeman ML, Liebler DC. Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane. *Chem Res Toxicol*. 2005; 18:1917–26. [PubMed: 16359182]
46. Roe SM, Ali MM, Meyer P, et al. The Mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). *Cell*. 2004; 116:87–98. [PubMed: 14718169]
47. Jiang Y, Bernard D, Yu Y, et al. Split Renilla luciferase protein fragment-assisted complementation (SRL-PFAC) to characterize Hsp90-Cdc37 complex and identify critical residues in protein/protein interactions. *J Biol Chem*. 285:21023–36. [PubMed: 20413594]
48. Rao R, Fiskus W, Yang Y, et al. HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells. *Blood*. 2008; 112:1886–93. [PubMed: 18591380]
49. Mi L, Hood BL, Stewart NA, et al. Identification of potential protein targets of isothiocyanates by proteomics. *Chem Res Toxicol*. 24:1735–43. [PubMed: 21838287]

Fig. 1. Sulforaphane induces proteasomal degradation of Hsp90 client proteins. (a) Mia Paca-2 and Panc-1 cells were treated with 15 μ M sulforaphane for different time periods. Sulforaphane induced a time-dependent down-regulation of Akt, Cdk4, and p53 mutant. Densitometry data are presented as mean $\pm$ SD ($n = 3$, $P < 0.05$). (b) Cells were treated with 5, 15, 25 μ M sulforaphane. Sulforaphane induced a concentration-dependent down-regulation of these proteins. Densitometry data are presented as mean $\pm$ SD ($n = 3$, $P < 0.05$). (c) Cells were pre-incubated with 10 μ M MG132 before sulforaphane treatment. Sulforaphane-induced down-regulation of Hsp90 client proteins were proteasome-mediated. SF, sulforaphane.

Fig. 2. Sulforaphane exhibits anticancer activity *in vitro* and *in vivo*. (a) Sulforaphane inhibited proliferation of Mia Paca-2, Panc-1, AsPc-1, and BxPc-3 cells. (b) Sulforaphane induced caspase-3 activity in Mia Paca-2 cells. Data are presented as means $\pm$ SD ($n = 3$, $P < 0.01$). (c) Anti-tumor effect of sulforaphane in xenografts. The pancreatic tumor xenograft model was generated by inoculating Mia Paca-2 cancer cells s.c. to the right and left flanks of nude mice. When the tumors reached 100–150 mm^3 , mice were randomly divided into three groups ($n = 6$) to receive vehicle, 25, or 50 mg/kg sulforaphane treatment (five times/week) for four weeks. Data are presented as means $\pm$ SD ($n = 6$, $P < 0.01$). (d) Mouse body weight was measured twice a week. SF, sulforaphane.

Fig. 3.

Influence of sulforaphane on ATP binding of Hsp90 and Hsp90-cochaperone association in Mia Paca-2 cells. (a) Sulforaphane (5, 15, 30 μM) did not affect ATP binding, while 17-AAG (5 μM) decreased ATP binding to Hsp90. (b) Sulforaphane reduced the amount of p50^{Cdc37} bound with Hsp90, while showed no effect on p23^{Sba1}. SF, sulforaphane.

Fig. 4.

Sulforaphane binding to Hsp90 mapped by NMR. (a) Rainbow representation of ^1H - ^{13}C -Ile methyl TROSY cross peaks of full length Hsp90 bound to sulforaphane (1.5 mM) (blue to red gradient indicates increasing intensities; peak centers, black dots). (b) Overlayed peak position plots of Hsp90 Ile methyl TROSY spectra in absence (black) and presence of sulforaphane (orange), significant shifts are encircled (Combined chemical shift difference $\Delta\nu = (0.25\Delta\nu_{\text{C}}^2 + \Delta\nu_{\text{H}}^2)^{1/2} > 0.01$ ppm). (c) Homology model of human Hsp90 bound to p23^{Sba1}. (Hsp90 protomers, gray; p23^{Sba1}, light orange). The shifting pattern upon sulforaphane binding is indicated as space fillings in one monomer (chemical shifts $\Delta\nu > 0.01$ ppm, orange side chains; $\Delta\nu > 0.015$, red side chains; no shifts, blue δ -methyl groups; no assignments or inconclusive results, grey δ -methyl groups; lid of the ATP pocket, green backbone; cysteines, yellow). (d) Surface representation of Hsp90, zoomed into peptide stretch IDIIPNPQER (Hsp90, gray; IDIIPNPQER stretch, cyan; isoleucines that shift upon sulforaphane binding, red (Ile 75) and orange (Ile 74)). (e) The Hsp90 N-terminal domain in complex with p50^{Cdc37}. (Hsp90, grey; p50^{Cdc37}, light orange; isoleucines and cysteines are colored as in (c)).

Fig. 5.

Proteolytic fingerprinting assay and LC-MS analysis of Hsp90 interaction with sulforaphane. (a) After incubation with DMSO or sulforaphane, protein sample (Hsp90βN) was digested with the indicated concentrations of trypsin. Hsp90 antibody (N-17), which detects N-terminus epitope of Hsp90, was used for immunoblotting. (b) Similarly, purified Hsp90βC protein was incubated with DMSO or sulforaphane, followed by trypsin digestion. The Hsp90 (AC88) antibody was used for immunoblotting. (c) Purified Hsp90βN was incubated with DMSO or sulforaphane (2 mM) for 30 min. Each sample was analyzed by LC-MS. (d) Purified Hsp90βN protein was incubated with DMSO or sulforaphane (2 mM)

for 30 min. The samples were digested with Trypsin for 24 hrs at 37 °C and analyzed by LC-MS. SF, sulforaphane

\$watermark-text

\$watermark-text

\$watermark-text